Executives On The Move: Defectors From GSK, Pfizer, Shire, Dr Reddy's Get New Posts
Executive Summary
Oxstem, ProMIS Neurosciences, resTORbio and Ultragenyx Pharmaceuticals are among firms recently announcing senior executive hires from the management ranks of big pharma. Meanwhile, Boehringer Ingelheim, Kane Biotech and Relypsa have all reported fresh resignations.
You may also be interested in...
Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.